SCHEMBL6263030

SCHEMBL6263030

CC(O)C1CCN(C)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.37
HRH3 Q9Y5N1 2/20 0.35
HRH4 Q9H3N8 1/20 0.35
GNAI3 P08754 3/20 0.32
GNAO1 P09471 3/20 0.32
GNAI1 P63096 3/20 0.32
QDPR P09417 2/20 0.31
HTR1A P08908 2/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
KDM4C Q9H3R0 1/20 0.31
CHRM2 P08172 1/20 0.31
ADRA2A P08913 1/20 0.31
CYP2D6 P10635 1/20 0.31
CHRM1 P11229 1/20 0.31
DRD1 P21728 1/20 0.31
SLC6A2 P23975 1/20 0.31
ADRA1A P35348 1/20 0.31
OPRM1 P35372 1/20 0.31
DRD3 P35462 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25784704 1.00 NCF1 (0.37) NCF1HRH3HRH4GNAI3GNAO1
SCHEMBL7513512 0.85
SCHEMBL20732401 0.81 NCF1 (0.39) NCF1HRH3HRH4GNAI3GNAO1
SCHEMBL22951415 0.80 NCF1 (0.34) NCF1HRH3HRH4GNAI3GNAO1
SCHEMBL8967209 0.78 NCF1 (0.38) NCF1GNAI3GNAO1GNAI1HTR1A
SCHEMBL12535764 0.78 NCF1 (0.38) NCF1HRH3HRH4GNAI3GNAO1
SCHEMBL22432101 0.78 NCF1 (0.40) NCF1HRH3HRH4GNAI3GNAO1
SCHEMBL105239 0.78 NCF1 (0.40) NCF1HRH3HRH4GNAI3GNAO1
SCHEMBL23103447 0.77 CHRNA7 (0.37) HRH3KDM4EALDH1A1CYP2D6KCNH2
SCHEMBL21104662 0.77 NCF1 (0.41) NCF1HRH3HRH4GNAI3GNAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026098635-A1 NEW CATIONIC LIPID WITH NITROGEN-CONTAINING HETEROCYCLIC HEAD GROUP AND USE THEREOF 厦门赛诺邦格生物科技股份有限公司 2026-05-15 WO disclosed
CN-117510397-A Styrene acetate compound and preparation method and application thereof 青海大学 2024-02-06 CN disclosed
CN-114369094-B Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors 正大天晴药业集团股份有限公司 2023-09-29 CN disclosed
US-20230029385-A1 2-METHYL-AZA-QUINAZOLINES BAYER AG (DE) 2023-01-26 US disclosed
CN-114761000-A Substituted 1, 6-naphthyridine inhibitors of CDK5 金翅雀生物公司 2022-07-15 CN disclosed
CN-114369094-A Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors 正大天晴药业集团股份有限公司 2022-04-19 CN disclosed
CN-111868059-B Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors 正大天晴药业集团股份有限公司 2021-12-03 CN disclosed
CN-111868059-A Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors 正大天晴药业集团股份有限公司 2020-10-30 CN disclosed
WO-2019185025-A1 TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR 正大天晴药业集团股份有限公司 2019-10-03 WO disclosed
EP-3303328-B1 AMINOESTER DERIVATIVES CHIESI FARM SPA (IT) 2019-03-20 EP disclosed
US-20080305081-A1 Novel aminopyrimidine derivatives as PLK1 inhibitors BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-12-11 US disclosed
US-20080305081-A1 Novel aminopyrimidine derivatives as PLK1 inhibitors BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-12-11 US disclosed
US-20080287397-A1 Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group TASHO PHARMACEUTICAL CO., LTD. (JP) 2008-11-20 US disclosed
US-20080287397-A1 Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group TASHO PHARMACEUTICAL CO., LTD. (JP) 2008-11-20 US disclosed
WO-2008081910-A1 NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-07-10 WO disclosed
EP-1787992-A1 Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group TAISHO PHARMACEUTICAL CO., LTD (JP) 2007-05-23 EP disclosed
EP-1002824-B1 AMINATED POLYSILAZANE AND PROCESS FOR THE PREPARATION THEREOF AZ ELECTRONIC MATERIALS USA (US) 2005-11-09 EP disclosed
WO-2003007959-A1 QUINOXALINE DERIVATIVES WHICH HAVE PARP INHIBITORY ACTION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-01-30 WO disclosed
US-6310168-B1 POLYSILAZANES WITH OXY PENDANT GOUPS TONEN CORPORATION (JP) 2001-10-30 US disclosed
EP-1002824-A1 AMINATED POLYSILAZANE AND PROCESS FOR THE PREPARATION THEREOF Tonen Corporation (JP) 2000-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287397-A1 Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group HRH2, HRH4, CRHR1 NCF1 517/4885HRH3 8/4885HRH4 2/4885
US-20080305081-A1 Novel aminopyrimidine derivatives as PLK1 inhibitors PLK1, AURKA, CDK1 NCF1 1592/4885HRH3 1060/4885HRH4 1564/4885
US-20230029385-A1 2-METHYL-AZA-QUINAZOLINES AZI2, DNMT1, TPMT NCF1 1064/4885HRH3 1526/4885HRH4 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.